Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 reMYND, Novo Nordisk Partner for Diabetes Treatment | Contract Pharma

What are you searching for?

Sign in

reMYND, Novo Nordisk Partner for Diabetes Treatment

reMYND could receive up to $350 million in milestone payments plus royalties

By: Betsy Louda

, Contract Pharma

reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND’s ReS39 therapeutic treatment for diabetes. This program holds also promise for NASH and the metabolic syndrome.  

 

ReS39 sustains and increases the endogenous insulin production capacity of the pancreas by restoring beta-cell function and insulin signalling in Type 1 and Type 2 diabetes animal models.

 

Koen De Witte, managing director of reMYND, said,  “Diabetes patients would greatly benefit from restoring durably their endogenous insulin production and/or increasing insulin sensitivity. Novo Nordisk’s agility to step-in once they observed the effects of our ReS39 treatment in their own hands makes the road ahead all the more exciting.”

 

Under the agreement, reMYND could receive up to 350 million Euros in research and milestone payments, plus royalties on resulting net sales.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters